Researchers conducted a major clinical trial to see if adding an immunotherapy drug called tislelizumab to standard chemotherapy before surgery would help patients with a specific type of lung cancer. The study involved 453 adults in China with stage II-IIIA non-small-cell lung cancer that could be removed by surgery. They compared patients who got tislelizumab plus chemotherapy before and after surgery to those who got a placebo plus the same chemotherapy.
After a median follow-up of about 38.5 months, the group receiving tislelizumab lived longer. The three-year overall survival rate was 79.3% for the tislelizumab group compared to 69.3% for the placebo group. The treatment also significantly delayed cancer recurrence or other negative events, with the median time not yet reached for the tislelizumab group versus 30.6 months for the placebo group.
The study reported that the safety of the tislelizumab regimen was tolerable and matched what is known about these types of drugs, but it did not provide detailed safety numbers. The main reason for caution is that all participants were from China, so the results may not directly translate to patients with different genetic backgrounds or healthcare systems. Readers should see this as strong evidence supporting this treatment approach for this specific group, but they should discuss with their doctor whether it is appropriate for their individual situation.
